VETARYS Announces Partnership with Antigenesis Biologics to Develop a Combination Immunotherapy to Treat Canine Cancers
VETARYS Announces Partnership with Antigenesis Biologics to Develop a Combination Immunotherapy to Treat Canine Cancers
PR Newswire
PEABODY, Mass., Oct. 26, 2026
PEABODY, Mass., Oct. 26, 2026 /PRNewswire/ -- Today, at the 2026 Boston Animal Health, Nutrition and Technology Innovation (AHNTI) Conference, VETARYS (www.vetarys.com) announced a research collaboration and option for an exclusive license for a canine combination immunotherapy being developed as a fusion protein by Antigenesis Biologics (www.antigenesis-bio.com), targeting solid tumors in dogs.
Antigenesis builds on the latest advances in proven human immunotherapies to develop first-in-class antibody therapeutics for companion animals, starting with canine oncology.
"Today's standard-of-care treatments for cancer in dogs remain largely limited to radiation and chemotherapy with variable efficacy and significant side effects," said Peter Hanson, Chief Scientific Officer at VETARYS. "The fusion protein being developed by Antigenesis combines two immunotherapies that together have demonstrated compelling improvements in survival and tumor shrinkage in the severe mouse melanoma model. Our target is to develop a subcutaneous therapy that can be administered by primary care veterinarians as a complement to veterinary oncology specialists, whose numbers are too few to reach every dog that needs cancer care."
About VETARYS
VETARYS, Inc. (formerly known as VetrixBio) is a biotechnology company focused on developing novel biologic therapies for companion animals. Guided by the belief that pets deserve better medicine, the company is advancing a pipeline targeting osteoarthritis and cancer—two of the most significant unmet needs in veterinary medicine. VETARYS centers on translating advances in biologics and immunotherapy into practical treatments designed to improve outcomes and quality of life for dogs and cats. Led by an experienced team spanning biotechnology, animal health, and commercialization, and supported by a network of scientific and clinical advisors, VETARYS is committed to bringing the next generation of veterinary medicines to market.
About Antigenesis
Antigenesis Biologics, Ltd. is a biotech company dedicated to addressing critical unmet needs in veterinary medicine. Leveraging our expertise in human therapeutics, we bring state-of-the-art advances to the significantly underserved veterinary market. Antigenesis develops targeted, safe, and effective treatments for oncology and other serious conditions, with a current pipeline focused on canine oncology and endocrine diseases. Our mission is to accelerate innovation and improve the health and well-being of our animal family members.
SOURCE VETARYS, Inc.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
This Once-Hot AI Stock Now Looks Deeply Undervalued
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
What 7 Key Market Indicators Are Telling Investors Right Now
United States